NASDAQ:UTHR - United Therapeutics Stock Price, Forecast & News

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

United Therapeutics Co. (NASDAQ:UTHR) released its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.34 by $0.82. The biotechnology company had revenue of $401.50 million for the quarter, compared to the consensus estimate of $342.28 million. United Therapeutics had a negative return on equity of 3.54% and a negative net margin of 6.04%. The firm's quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter last year, the business posted $3.98 EPS. View United Therapeutics' Earnings History.

United Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for United Therapeutics.

10 brokers have issued 1 year price targets for United Therapeutics' shares. Their forecasts range from $80.00 to $273.00. On average, they expect United Therapeutics' share price to reach $119.70 in the next year. This suggests a possible upside of 29.3% from the stock's current price. View Analyst Price Targets for United Therapeutics.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 2 sell ratings, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for United Therapeutics.

News stories about UTHR stock have trended negative on Tuesday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. United Therapeutics earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for United Therapeutics.

Some companies that are related to United Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Celgene (CELG), Gilead Sciences (GILD), General Electric (GE), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), NVIDIA (NVDA), Allergan (AGN), CytoDyn (CYDY), Skyworks Solutions (SWKS) and Johnson & Johnson (JNJ).

United Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (4.28%), First Trust Advisors LP (1.83%), Point72 Asset Management L.P. (1.46%), Krensavage Asset Management LLC (1.23%), Great Point Partners LLC (1.07%) and Pictet Asset Management Ltd. (0.92%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.

UTHR stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Denali Advisors LLC, Railway Pension Investments Ltd, Robeco Institutional Asset Management B.V., Russell Investments Group Ltd., Voloridge Investment Management LLC, Hussman Strategic Advisors Inc. and Krensavage Asset Management LLC. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Patusky, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Insider Buying and Selling for United Therapeutics.

UTHR stock was bought by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Point72 Asset Management L.P., Sector Gamma AS, Squarepoint Ops LLC, Tamarack Advisers LP, Virginia Retirement Systems ET AL, Parametric Portfolio Associates LLC and State of New Jersey Common Pension Fund D. View Insider Buying and Selling for United Therapeutics.

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of UTHR stock can currently be purchased for approximately $92.56.

United Therapeutics has a market capitalization of $4.06 billion and generates $1.63 billion in revenue each year. The biotechnology company earns $589.20 million in net income (profit) each year or $13.39 on an earnings per share basis. United Therapeutics employs 860 workers across the globe.View Additional Information About United Therapeutics.

The official website for United Therapeutics is http://www.unither.com/.

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]